{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:48:43Z","timestamp":1792586923215,"version":"4.5.0"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"DOI":"10.3389\/fcimb.2020.572681","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T05:54:30Z","timestamp":1603346070000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":189,"title":["Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine"],"prefix":"10.3389","volume":"10","author":[{"given":"Rahul","family":"Shukla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viswanathan","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajgokul K.","family":"Shanmugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/s41591-018-0056-0","article-title":"Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys","volume":"24","author":"Abbink","year":"2018","journal-title":"Nat. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.cmi.2018.01.018","article-title":"Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America","volume":"24","author":"Arredondo-Garc\u00eda","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"B3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nature18938","article-title":"Structural basis of potent Zika-dengue virus antibody cross-neutralization","volume":"536","author":"Barba-Spaeth","year":"2016","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1126\/science.aal4365","article-title":"Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity","volume":"356","author":"Bardina","year":"2017","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","first-page":"304ra141","DOI":"10.1126\/scitranslmed.aaa3787","article-title":"Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination","volume":"7","author":"Beatty","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1086\/526790","article-title":"Cross-reactive memory CD8 + T cells alter the immune response to heterologous secondary dengue virus infections in mice in a sequence-specific manner","volume":"197","author":"Beaumier","year":"2008","journal-title":"J. Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.chom.2010.08.007","article-title":"The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity","volume":"8","author":"Beltramello","year":"2010","journal-title":"Cell Host Microbe"},{"key":"B8","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.immuni.2019.01.005","article-title":"Dengue virus immunity increases zika virus-induced damage during pregnancy","volume":"50","author":"Brown","year":"2019","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"12479","DOI":"10.1073\/pnas.1106568108","article-title":"Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection","volume":"108","author":"Chan","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.3892\/mmr.2016.5454","article-title":"Functional properties of DENV EDIII-reactive antibodies in human DENV-1-infected sera and rabbit antiserum to EDIII","volume":"14","author":"Chen","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.micinf.2006.09.009","article-title":"The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry","volume":"9","author":"Chin","year":"2007","journal-title":"Microbes Infect."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.4049\/jimmunol.1500057","article-title":"Dengue virus nonstructural protein 1-induced antibodies cross-react with human plasminogen and enhance its activation","volume":"196","author":"Chuang","year":"2016","journal-title":"J. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"13759","DOI":"10.1128\/JVI.02166-14","article-title":"Molecular mimicry between dengue virus and coagulation factors induces antibodies to inhibit thrombin activity and enhance fibrinolysis","volume":"88","author":"Chuang","year":"2014","journal-title":"J. Virol."},{"key":"B15","unstructured":"Phase II, Randomized, Double-blind, Clinical Trial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50\u201370 Years in Taiwan2020"},{"key":"B16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.str.2012.01.001","article-title":"Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody","volume":"20","author":"Cockburn","year":"2012","journal-title":"Structure"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7769","DOI":"10.1128\/JVI.75.16.7769-7773.2001","article-title":"Monoclonal antibodies that bind to domain III of dengue virus e glycoprotein are the most efficient blockers of virus adsorption to vero cells","volume":"75","author":"Crill","year":"2001","journal-title":"J. Virol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.coi.2017.07.001","article-title":"The immunopathology of dengue and Zika virus infections","volume":"19","author":"Culshaw","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"a029371","DOI":"10.1101\/cshperspect.a029371","article-title":"Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination?: The path to a dengue vaccine: learning from human natural dengue infection studies and vaccine trials","volume":"10","author":"de Silva","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/ni.3515","article-title":"Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus","volume":"17","author":"Dejnirattisai","year":"2016","journal-title":"Nat. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ni.3058","article-title":"A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus","volume":"16","author":"Dejnirattisai","year":"2015","journal-title":"Nat. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/vaccines8010063","article-title":"A review on dengue vaccine development","volume":"8","author":"Deng","year":"2020","journal-title":"Vaccines"},{"key":"B24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1099\/0022-1317-59-2-273","article-title":"Demonstration of interference between dengue virus types in cultured mosquito cells using monoclonal antibody probes","volume":"59","author":"Dittmar","year":"1982","journal-title":"J. Gen. Virol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"11726","DOI":"10.1128\/JVI.01140-14","article-title":"Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition","volume":"88","author":"Dowd","year":"2014","journal-title":"J. Virol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1586\/erv.10.159","article-title":"Unique challenges faced by the clinical evaluation of dengue vaccines","volume":"10","author":"Edelman","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"B27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4269\/ajtmh.2003.69.48","article-title":"Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine","volume":"69","author":"Edelman","year":"2003","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B28","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ebiom.2016.10.006","article-title":"Protective role of cross-reactive CD8 T cells against dengue virus infection","volume":"13","author":"Elong Ngono","year":"2016","journal-title":"EBioMed"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/ni.3849","article-title":"Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection","volume":"18","author":"Fernandez","year":"2017","journal-title":"Nat. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.aaa8651","article-title":"Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers","volume":"349","author":"Fibriansah","year":"","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","first-page":"7585","DOI":"10.1128\/JVI.00757-13","article-title":"Structural changes in dengue virus when exposed to a temperature of 37 C","volume":"87","author":"Fibriansah","year":"2013","journal-title":"J. Virol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/emmm.201303404","article-title":"A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface","volume":"6","author":"Fibriansah","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"6341","DOI":"10.1038\/ncomms7341","article-title":"A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins","volume":"6","author":"Fibriansah","year":"","journal-title":"Nat. Commun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/srep00051","article-title":"Cross-reactivity and expansion of dengue-specific t cells during acute primary and secondary infections in humans","volume":"1","author":"Friberg","year":"2011","journal-title":"Sci. Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"9422","DOI":"10.1073\/pnas.0703498104","article-title":"Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention","volume":"104","author":"Goncalvez","year":"2007","journal-title":"Proc. Natl. Acad. Sci U.S.A."},{"key":"B36","doi-asserted-by":"publisher","first-page":"8828","DOI":"10.1128\/JVI.00606-08","article-title":"Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus","volume":"82","author":"Gromowski","year":"2008","journal-title":"J. Virol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"6355","DOI":"10.1016\/j.vaccine.2017.09.089","article-title":"Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age","volume":"35","author":"Halstead","year":"2017","journal-title":"Vaccine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S1473-3099(10)70166-3","article-title":"Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes","volume":"10","author":"Halstead","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1084\/jem.146.1.201","article-title":"Dengue viruses and mononuclear phagocytes: I. Infection enhancement by non-neutralizing antibody","volume":"146","author":"Halstead","year":"1977","journal-title":"J. Exp. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/infdis\/jiw576","article-title":"Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue-exposed individuals","volume":"215","author":"Henein","year":"2017","journal-title":"J. Infect. Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.2149\/tmh.2011-S03","article-title":"Dengue virus receptor","volume":"39","author":"Hidari","year":"2011","journal-title":"Trop. Med. Health"},{"key":"B43","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.virusres.2008.07.022","article-title":"Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells","volume":"137","author":"Huerta","year":"2008","journal-title":"Virus Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1128\/JVI.78.1.378-388.2004","article-title":"An external loop region of domain iii of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells","volume":"78","author":"Hung","year":"2004","journal-title":"J. Virol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"8353","DOI":"10.1128\/JVI.00696-10","article-title":"Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles","volume":"84","author":"Junjhon","year":"2010","journal-title":"J. Virol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"10776","DOI":"10.1128\/JVI.01180-08","article-title":"Differential modulation of prM cleavage, extracellular particle distribution, and virus infectivity by conserved residues at nonfurin consensus positions of the dengue virus pr-M junction","volume":"82","author":"Junjhon","year":"2008","journal-title":"J. Virol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1016\/S0264-410X(01)00020-2","article-title":"Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers","volume":"19","author":"Kanesa-Thasan","year":"2001","journal-title":"Vaccine"},{"key":"B48","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1126\/science.abb6143","article-title":"Zika virus infection enhances future risk of severe dengue disease","volume":"369","author":"Katzelnick","year":"2020","journal-title":"Science"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.tibtech.2019.03.013","article-title":"Production and biomedical application of flavivirus-like particles","volume":"37","author":"Krol","year":"2019","journal-title":"Trends Biotechnol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.virol.2015.03.025","article-title":"Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host","volume":"221","author":"Kuhn","year":"2015","journal-title":"Virology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1586\/14760584.2016.1106318","article-title":"Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates?","volume":"15","author":"Lam","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"B53","doi-asserted-by":"publisher","first-page":"aaf8160","DOI":"10.1126\/science.aaf8160","article-title":"Assessing the global threat from Zika virus","volume":"353","author":"Lessler","year":"2016","journal-title":"Science"},{"key":"B54","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1600-065X.2008.00678.x","article-title":"Understanding the contribution of cellular immunity to dengue disease pathogenesis","volume":"225","author":"Mathew","year":"2008","journal-title":"Immunol. Rev."},{"key":"B55","doi-asserted-by":"publisher","first-page":"304ra142","DOI":"10.1126\/scitranslmed.aaa3863","article-title":"Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity","volume":"7","author":"Modhiran","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.coviro.2014.01.009","article-title":"Relating structure to evolution in class II viral membrane fusion proteins","volume":"5","author":"Modis","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"6986","DOI":"10.1073\/pnas.0832193100","article-title":"A ligand-binding pocket in the dengue virus envelope glycoprotein","volume":"100","author":"Modis","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B58","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1586\/14760584.4.4.553","article-title":"Yellow fever vaccine","volume":"4","author":"Monath","year":"2005","journal-title":"Expert Rev. Vaccines"},{"key":"B59","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3390\/pathogens9040247","article-title":"Non-human primate models of dengue virus infection: a comparison of viremia levels and antibody responses during primary and secondary infection among old world and new world monkeys","volume":"9","author":"Muhammad Azami","year":"2020","journal-title":"Pathogens"},{"key":"B60","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0140-6736(15)61273-9","article-title":"Zika virus: following the path of dengue and chikungunya?","volume":"386","author":"Musso","year":"2015","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","first-page":"8546","DOI":"10.1128\/JVI.00736-12","article-title":"Genome-wide patterns of intrahuman dengue virus diversity reveal associations with viral phylogenetic clade and interhost diversity","volume":"86","author":"Parameswaran","year":"2012","journal-title":"J. Virol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.chom.2017.08.003","article-title":"Intrahost selection pressures drive rapid dengue virus microevolution in acute human infections","volume":"22","author":"Parameswaran","year":"2017","journal-title":"Cell Host Microbe"},{"key":"B63","first-page":"747","article-title":"Flaviviruses","volume-title":"Fields Virology","author":"Pierson","year":"2013"},{"key":"B64","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.str.2012.01.014","article-title":"Capturing a virus while it catches its breath","volume":"20","author":"Pierson","year":"2012","journal-title":"Structure"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/S1473-3099(18)30063-X","article-title":"Development of vaccines against Zika virus","volume":"18","author":"Poland","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e1005738","DOI":"10.1371\/journal.ppat.1005738","article-title":"Dengue virus NS1 disrupts the endothelial glycocalyx, leading to hyperpermeability","volume":"12","author":"Puerta-Guardo","year":"2016","journal-title":"PLOS Pathog."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e0006191","DOI":"10.1371\/journal.pntd.0006191","article-title":"A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice","volume":"12","author":"Ramasamy","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"206","DOI":"10.15252\/embr.201745302","article-title":"The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design","volume":"19","author":"Rey","year":"2018","journal-title":"EMBO Rep."},{"key":"B69","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0065-3527(03)59009-1","article-title":"Microevolution and virulence of dengue viruses","volume":"59","author":"Rico-Hesse","year":"2003","journal-title":"Adv. Virus Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3389\/fcimb.2019.00200","article-title":"Molecular simulations reveal the role of antibody fine specificity and viral maturation state on antibody-dependent enhancement of infection in dengue virus","volume":"9","author":"Ripoll","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cell.2015.06.057","article-title":"Structure-guided design of an anti-dengue antibody directed to a non-immunodominant epitope","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e1000718","DOI":"10.1371\/journal.ppat.1000718","article-title":"Immature dengue virus: a veiled pathogen?","volume":"6","author":"Rodenhuis-Zybert","year":"2010","journal-title":"PLoS Pathog."},{"key":"B73","doi-asserted-by":"publisher","first-page":"15411","DOI":"10.1038\/ncomms15411","article-title":"Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope","volume":"8","author":"Rouvinski","year":"2017","journal-title":"Nat. Commun."},{"key":"B74","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature14130","article-title":"Recognition determinants of broadly neutralizing human antibodies against dengue viruses","volume":"520","author":"Rouvinski","year":"2015","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4269\/ajtmh.2002.66.264","article-title":"Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses","volume":"66","author":"Sabchareon","year":"2002","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"B77","unstructured":"Background Paper on Yellow Fever Vaccine2013"},{"key":"B78","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41586-018-0157-4","article-title":"Reconstruction of antibody dynamics and infection histories to evaluate dengue risk","volume":"557","author":"Salje","year":"2018","journal-title":"Nature"},{"key":"B79","doi-asserted-by":"publisher","first-page":"a029520","DOI":"10.1101\/cshperspect.a029520","article-title":"Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination?: the challenges of a dengue vaccine","volume":"10","author":"Screaton","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nri3916","article-title":"New insights into the immunopathology and control of dengue virus infection","volume":"15","author":"Screaton","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"102991","DOI":"10.1016\/j.ebiom.2020.102991","article-title":"Dengue and zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models","volume":"60","author":"Shukla","year":"2020","journal-title":"EBioMed"},{"key":"B82","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/14760584.2019.1562909","article-title":"Next generation designer virus-like particle vaccines for dengue","volume":"2","author":"Shukla","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"B83","doi-asserted-by":"publisher","first-page":"5665","DOI":"10.1128\/JVI.79.9.5665-5675.2005","article-title":"Early T-cell responses to dengue virus epitopes in vietnamese adults with secondary dengue virus infections","volume":"79","author":"Simmons","year":"2005","journal-title":"J. Virol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMra1110265","article-title":"Dengue","volume":"366","author":"Simmons","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41590-018-0210-3","article-title":"The immune response against flaviviruses","volume":"19","author":"Slon Campos","year":"2018","journal-title":"Nat. Immunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/s41590-019-0477-z","article-title":"A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection","volume":"20","author":"Slon-Campos","year":"2019","journal-title":"Nat. Immunol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1128\/JVI.00247-14","article-title":"Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones","volume":"87","author":"Smith","year":"2014","journal-title":"J. Virol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1128\/JVI.06335-11","article-title":"Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection","volume":"86","author":"Smith","year":"2012","journal-title":"J. Virol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41577-019-0123-x","article-title":"Adaptive immune responses to primary and secondary dengue virus infections","volume":"19","author":"St. John","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1016\/j.ijid.2019.01.029","article-title":"Dengue vaccine development: global and Indian scenarios","author":"Swaminathan","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"B92","doi-asserted-by":"publisher","first-page":"e01123","DOI":"10.1128\/mBio.01123-16","article-title":"Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against zika virus","volume":"7","author":"Swanstrom","year":"2016","journal-title":"MBio"},{"key":"B93","doi-asserted-by":"publisher","first-page":"139r","DOI":"10.1126\/scitranslmed.3003888","article-title":"The structural basis for serotype-specific neutralization of dengue virus by a human antibody","volume":"4","author":"Teoh","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"e00745","DOI":"10.1128\/JVI.00745-20","article-title":"Dimerization of dengue virus E subunits impacts antibody function and domain focus","volume":"94","author":"Thomas","year":"2020","journal-title":"J. Virol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia\u00ae: development to deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"B96","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.3389\/fimmu.2019.02125","article-title":"Human T cell response to dengue virus infection","volume":"10","author":"Tian","year":"2019","journal-title":"Front. Immunol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/S0140-6736(20)30556-0","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2\u201317 years: a randomised, placebo-controlled, phase 2 trial","volume":"395","author":"Tricou","year":"2020","journal-title":"Lancet"},{"key":"B98","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.1128\/JVI.00273-15","article-title":"Complexity of neutralizing antibodies against multiple dengue virus serotypes after heterotypic immunization and secondary infection revealed by in-depth analysis of cross-reactive antibodies","volume":"84","author":"Tsai","year":"2015","journal-title":"J. Virol."},{"key":"B99","unstructured":"BLA Approval for Dengue Tetravalent Vaccine, Live2019"},{"key":"B100","doi-asserted-by":"publisher","first-page":"7091","DOI":"10.1016\/j.vaccine.2015.09.053","article-title":"Next generation dengue vaccines: a review of the preclinical development pipeline","volume":"33","author":"Vannice","year":"2015","journal-title":"Vaccine"},{"key":"B101","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"10813","DOI":"10.1016\/j.virol.2009.06.037","article-title":"Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody","volume":"88","author":"Wahala","year":"2009","journal-title":"Virology"},{"key":"B103","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.1128\/JVI.00216-15","article-title":"Dengue virus infection with highly neutralizing levels of cross-reactive antibodies causes acute lethal small intestinal pathology without a high level of viremia in mice","volume":"89","author":"Watanabe","year":"2015","journal-title":"J. Virol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1128\/JVI.02129-14","article-title":"The human CD8 + T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes","volume":"87","author":"Weiskopf","year":"2015","journal-title":"J. Virol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"E2046","DOI":"10.1073\/pnas.1305227110","article-title":"Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells","volume":"110","author":"Weiskopf","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B106","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.4049\/jimmunol.0801974","article-title":"A protective role for dengue virus-specific CD8 + T cells","volume":"182","author":"Yauch","year":"2009","journal-title":"J. Immunol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"6494","DOI":"10.1128\/JVI.00036-15","article-title":"CD8 + T cells can mediate short-term protection against heterotypic dengue virus reinfection in mice","volume":"89","author":"Zellweger","year":"2015","journal-title":"J. Virol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2020.572681\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T05:54:38Z","timestamp":1603346078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2020.572681\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":107,"alternative-id":["10.3389\/fcimb.2020.572681"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2020.572681","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"article-number":"572681"}}